Strategic Partners A/S OZYMF
Set alert
At close · Oct 30
- YTD
- 0.00%
- 1 year
- 0.00%
- Open
- 0.091
- Prev close
- 90.00
- Mkt cap
- 4.84M
- Vol
- 3.25K
- Avg vol
- 0
- EPS
- -2,471.19
- P/E
- 0.00
More statistics
- Low
- 0.09
- High
- 0.091
News
4 years ago globenewswire.com
Orphazyme completes sale of substantially all of its assets and business activities to KemPharm
Orphazyme A/SCompany announcement No. 29/2022 Inside information www.orphazyme.com Company Registration No. 32266355
4 years ago globenewswire.com
Orphazyme A/S under In-Court-Restructuring to sell substantially all of its assets and business activities to KemPharm, Inc.
Orphazyme A/S in restructuring Company announcement No. 24/2022Inside information www.orphazyme.com Company Registration No. 32266355
5 years ago benzinga.com
Why Entera Bio, Orphazyme, Bellerophon Are Moving Today
Entera Bio Ltd. (NASDAQ: ENTX), Orphazyme A/S (NASDAQ: ORPH) and Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) are among the biggest biopharma movers Wednesday.
5 years ago globenewswire.com
Kim Stratton, CEO, resigns from Orphazyme
Orphazyme A/SCompany announcement No. 72/2020Inside informationCompany Registration No. 32266355
5 years ago businesswire.com
CytRx Highlights Orphazyme's Submission of European Marketing Authorisation for Arimoclomol to Treat Niemann-Pick Disease Type C
LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and…
6 years ago globenewswire.com
Orphazyme closes its global offering, consisting of an initial public offering of American Depositary Shares in the U.S. and a concurrent private placement of ordinary shares in Europe
Orphazyme A/S has today registered a capital increase of new ordinary shares and completed its global offering, consisting of an initial public offering of American Depositary Shares (“ADSs”) in the…
6 years ago globenewswire.com
Orphazyme announces U.S. FDA acceptance and Priority Review of New Drug Application for arimoclomol for Niemann-Pick disease Type C
Orphazyme A/SCompany announcement No. 50/2020 Company Registration No. 32266355